Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA

LONDON, November 18, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Geron Corporation (NASDAQ: GERN), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Galena Biopharma Inc. (NASDAQ: GALE), and XOMA Corporation (NASDAQ: XOMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 17, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,647.75, up 0.07% and the NASDAQ Composite closed at 4,671.00, down 0.37%. The S&P 500 finished the session 0.07% higher at 2,041.32. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 781.08, up 0.49%, with the index advancing 9.06% in the previous three months. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

Exelixis Inc.'s stock gained 1.73%, to close the day at $1.76. The stock recorded a trading volume of 0.97 million shares, much below its three months average volume of 3.91 million shares. The company's shares oscillated between $1.71 and $1.78 during the session. Over the last one month, Exelixis Inc.'s shares have gained 11.75%. However, the stock has declined 58.10% in the past three months and 71.29% since the start of this year. The stock is trading above its 50-day moving average of $1.66, while the 50-day moving average is below the 200-day moving average of $3.69. Additionally, the stock has a Relative Strength Index (RSI) of 49.63. Sign up and read the free notes on EXEL at:

www.Investor-Edge.com/EXEL-18Nov2014

On Monday, shares in Geron Corp. recorded a trading volume of 13.84 million shares, well above its three months average volume of 2.99 million shares. The stock ended the day at $2.98, which was 7.97% above its previous day's closing of $2.76, and registered an intraday range of $2.74 and $3.10. Geron Corp.'s shares have surged 25.74% in the previous three trading sessions, 41.23% in the last one month, and 23.65% on YTD in the past three months. The stock is trading above its 50-day and 200-day moving averages of $2.24 and $2.54, respectively. Furthermore, shares of Geron Corp. have an RSI of 63.98. The complimentary notes on GERN can be downloaded as in PDF format at:

www.Investor-Edge.com/GERN-18Nov2014

Tekmira Pharmaceuticals Corp.'s stock rallied 5.06% to end Monday's session at $17.24. The stock recorded a trading volume of 0.87 million shares, much below its three months average volume of 4.13 million shares. The company's shares fluctuated between $16.71 and $17.44 during the session. Tekmira Pharmaceuticals Corp.'s shares have rallied 116.31% since the beginning of 2014 and 7.08% in the previous three trading sessions. However, the stock has lost 20.77% over the last one month and 4.65% in the previous three months. The stock is trading below its 50-day and 200-day moving averages. Tekmira Pharmaceuticals Corp.'s shares 50-day moving average of $20.20 is above its 200-day moving average of $17.30. Additionally, the stock has an RSI of 41.00. On the same day, Tekmira Pharmaceuticals Corp. announced licensing of its proprietary lipid nanoparticle (LNP) delivery technology with Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA) for exclusive use in Dicerna's primary hyperoxaluria type 1 (PH1) development program. Register for free on Investor-Edge and access the latest research on TKMR at:

www.Investor-Edge.com/TKMR-18Nov2014

On Monday, shares in Galena Biopharma Inc. fluctuated between $1.80 and $1.89 before ending the session 3.21% lower at $1.81. The stock reported a trading volume of 0.90 million shares, lower than its three months average volume of 1.58 million shares. Galena Biopharma Inc.'s stock has lost 5.73% in the previous three trading sessions, 2.69% in the last one month, and 63.51% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $2.02 and $2.64, respectively. Moreover, shares of Galena Biopharma Inc. have an RSI of 44.38. The complete research on GALE is available for free at:

www.Investor-Edge.com/GALE-18Nov2014

XOMA Corp.'s stock finished Monday's session 1.53% higher at $3.98. A total of 0.60 million shares were traded, which was below its three months average volume of 1.32 million shares. The stock vacillated between $3.90 and $4.03 during the session. Over the last one month and over the past three months, XOMA Corp.'s shares have fallen by 1.12% and 7.44%, respectively. Additionally, from the beginning of 2014, the stock has declined 40.86%. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $4.80 is greater than its 50-day moving average of $4.23. XOMA Corp.'s stock has an RSI of 43.06. Free in depth research on XOMA is available at:

www.Investor-Edge.com/XOMA-18Nov2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED